DB:AMU

Stock Analysis Report

Executive Summary

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States.


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has AMAG Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMU's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.8%

AMU

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-51.0%

AMU

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: AMU underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: AMU underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

AMUIndustryMarket
7 Day2.8%11.7%9.9%
30 Day-20.6%-5.9%-16.6%
90 Day-49.1%-22.6%-24.8%
1 Year-51.0%-51.0%-7.9%-8.1%-15.0%-17.5%
3 Year-72.9%-72.9%16.6%15.4%-17.4%-24.5%
5 Year-89.3%-89.3%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is AMAG Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AMAG Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMU (€5.35) is trading below our estimate of fair value (€28.62)

Significantly Below Fair Value: AMU is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMU is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AMU is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMU is good value based on its PB Ratio (0.7x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is AMAG Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

92.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: AMU is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMU's is expected to become profitable in the next 3 years.

Revenue vs Market: AMU's revenue is expected to decline over the next 3 years (-8.9% per year).

High Growth Revenue: AMU's revenue is forecast to decline over the next 3 years (-8.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AMU's Return on Equity is forecast to be low in 3 years time (1.3%).


Next Steps

Past Performance

How has AMAG Pharmaceuticals performed over the past 5 years?

-69.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMU is currently unprofitable.

Growing Profit Margin: AMU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMU is unprofitable, and losses have increased over the past 5 years at a rate of -69.4% per year.

Accelerating Growth: Unable to compare AMU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: AMU has a negative Return on Equity (-163.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is AMAG Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AMU's short term assets ($316.6M) exceed its short term liabilities ($208.2M).

Long Term Liabilities: AMU's short term assets ($316.6M) exceed its long term liabilities ($296.9M).


Debt to Equity History and Analysis

Debt Level: AMU's debt to equity ratio (96.8%) is considered high.

Reducing Debt: AMU's debt to equity ratio has reduced from 107.1% to 96.8% over the past 5 years.


Balance Sheet

Inventory Level: AMU has a low level of unsold assets or inventory.

Debt Coverage by Assets: AMU's debt is covered by short term assets (assets are 1.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMU has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AMU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AMAG Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AMU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMU's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Bill Heiden (59yo)

7.83s

Tenure

US$4,966,215

Compensation

Dr. William K. Heiden, also known as Bill, has been the Chief Executive Officer of AMAG Pharmaceuticals, Inc. since May 14, 2012 and serves as its President. Dr. Heiden serves as the Managing Director of V ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD4.97M) is above average for companies of similar size in the German market ($USD765.33K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
William Heiden
CEO, President & Director7.83yrsUS$4.97m0.62% $1.2m
Edward Myles
Executive VP3.83yrsUS$1.54m0.080% $153.7k
Julie Krop
Executive VP of Clinical Development & Regulatory Affairs and Chief Medical Officer4.67yrsUS$1.63m0.10% $197.1k
Linda Lennox
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Joseph Vittiglio
Executive VP of Legal Affairs & Quality4.58yrsUS$1.20m0.081% $157.0k
Tracy Berns
Chief Compliance Officer2.42yrsno datano data
Amit Verma
Vice President of Marketing6.67yrsno datano data
Kelly Schick
Senior VP & Chief Human Resources Officerno datano data0.021% $40.8k
Anthony Casciano
Executive VP & Chief Commercial Officer3.42yrsno data0.030% $57.2k
Laura Williams
Senior Vice President of Clinical Development2.42yrsno datano data

4.2yrs

Average Tenure

47yo

Average Age

Experienced Management: AMU's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Heiden
CEO, President & Director7.83yrsUS$4.97m0.62% $1.2m
James Sulat
Independent Director5.83yrsUS$237.98k0.038% $73.8k
Davey Scoon
Independent Director13.25yrsUS$254.98k0.064% $123.3k
Robert Perez
Independent Director11.17yrsUS$229.98k0.064% $123.3k
Barbara Deptula
Independent Director6.42yrsUS$240.98k0.043% $82.4k
Gino Santini
Independent Chairman5.83yrsUS$282.98k0.057% $109.7k
John Fallon
Independent Director5.42yrsUS$247.48k0.045% $86.6k
Anne Phillips
Independent Director0.83yrno datano data
David Johnson
Independent Director0.42yrno datano data
Kathrine O'Brien
Independent Director0.83yrno datano data

5.8yrs

Average Tenure

63yo

Average Age

Experienced Board: AMU's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AMAG Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AMAG Pharmaceuticals, Inc.
  • Ticker: AMU
  • Exchange: DB
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$211.762m
  • Listing Market Cap: US$192.704m
  • Shares outstanding: 34.27m
  • Website: https://www.amagpharma.com

Number of Employees


Location

  • AMAG Pharmaceuticals, Inc.
  • 1100 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMAGNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1986
AMUDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1986
AMUBRSE (Berne Stock Exchange)YesCommon StockCHCHFJun 1986

Biography

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company’s products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 22:39
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.